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ABSTRACT  
Glycosylation alterations are frequently observed in cancer cells and shape tumor progression. In this 
issue of Cancer Cell, Nguyen et al. show that GALNT1 relocation from Golgi to endoplasmic reticulum 
drives liver tumor growth and invasion, due to enhanced glycosylation and consequential activation 
of the extracellular matrix-degrading metalloproteinase MMP14. 
___________________________________________________________________________________ 
Glycosylation is a complex and finely regulated cellular process that depends on the coordinated 
action of several glycosyltransferases and glycosidases, exerting a variety of functional roles in 
physiological and pathological conditions. An highly abundant form of protein posttranslational 
modification is the GalNAc O-glycosylation, an enzymatic process initiated by a family of up to 20 
homologous genes encoding UDP-GalNAc:polypeptide GalNAc-transferases (GALNTs) (EC 2.4.1.41). 
The GALNTs mediate the GalNAcα1-O-serine / threonine linkage in O-glycoproteins. Although 
catalyzing the same enzymatic step, each GALNT isoform displays different, though sometimes 
partly overlapping, acceptor peptide substrate preferences and kinetics features (Bennet et al., 2012). 
The acceptor peptide specificities comprise both unmodified sequences and previously glycosylated 
GalNAc-peptide substrates, including the effect of the C-terminal GALNT lectin domain that drives 
the specificity towards partially glycosylated GalNAc-peptide substrates (Bennett et al., 2012; 
Revoredo et al., 2016). In addition, GALNT genes display highly controlled cell and tissue expression 
profiles during development and differentiation. These features are key factors orchestrating the 
unique cell O-glycoproteome. Classically, GalNAc O-glycosylation of proteins is initiated in the Golgi 
apparatus after most protein folding events have occurred. In contrast, protein N-Glycosylation and 
other types of O-glycosylation (including the addition of O-mannose and O-fucose on proteins in the 
secretory pathway) are initiated in the endoplasmic reticulum (ER) (Bennett et al., 2012). 
The cellular glycosylation pattern is recognized to be crucial for several biological functions in normal 
and disease states. Alterations in enzymes that control different glycosylation steps, resulting in 
aberrant glycan products, have a clear association with tumor progression, regulating proliferation, 
invasion and metastasis processes (Pinho and Reis, 2015). Previous studies have reported altered 
expression of GALNTs during malignant transformation in different types of cancer with association 
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with clinicopathological features, such as the presence of venous invasion (Gomes et al., 2009; Pinho 
and Reis, 2015)  
Liver cancer is a major cause of cancer-related death, mainly associated with late diagnosis and 
frequent metastasis formation. In hepatocellular carcinoma, the most common form of liver cancer, 
GALNT1 is commonly up-regulated and associated with poor patient survival. Furthermore, its 
knockdown has been shown to decrease liver cancer cells migration and invasion capacities (Huang 
et al., 2015). In this issue of Cancer Cell, Nguyen et al. show, besides the striking increase of GALNT1 
and of its product, the Tn antigen (GalNAcα1-O-serine / threonine), that the subcellular localization 
of Tn changes in liver tumor cells. This increased Tn expression was proposed to occur upon the 
intracellular relocation of GALNT1 from the Golgi to the ER (Nguyen et al., 2017). The mechanism of 
GALNTs redistribution to the ER has been previously reported to be controlled by the activation of 
Src tyrosine kinase and COP-I dependent trafficking events (Gill et al., 2010). This mechanism, named 
the GALA pathway, is based on the relocation of GALNTs leading to increased levels of expression of 
GALNT mediated O-glycosylation and the Tn antigen expression. ER-location of O-glycosylation has 
been associated with more aggressive cancer cell features, such as increased migration and invasion 
(Gill et al., 2013).   
Glycans are key players in extracellular matrix (ECM) remodeling. The interactions between cell and 
ECM are essential for defining an invasive and migratory phenotype (Pinho and Reis, 2015). Using a 
mouse liver cancer model artificially expressing GALNT1, Nguyen et al. show that the localization of 
GALNT1 in the ER resulted in increased O-GalNAc glycosylation of various proteins, such as the ER-
resident protein PDIA4 and the matrix metalloproteinase-14 (MMP14) (Nguyen et al., 2017). 
Glycosylation has been previously shown to be important in regulating the activity of matrix 
metalloproteinases (Boon et al., 2016). Increased activity of the glycosylated MMP14 has been 
associated with malignant phenotype and metastasis. Nguyen et al. demonstrate an augmented 
glycosylation of MMP14 produced in cells whose GALNT1 was localized in the ER as compared to 
Golgi localization, which led to an enhancement in MMP14 activity, potentiating matrix degradation 
and therefore tumor growth (Nguyen et al., 2017) (Figure 1). 
Furthermore, the ER GALNT1 relocation observed in this liver cancer model and concomitant 
enhanced O-glycosylation was accompanied by a marked increase of circulating tumor cells, which 
is in line with the high metastatic potential observed (Nguyen et al., 2017).  
Overall, the activation of a pathway leading to early O-GalNAc glycosylation of proteins may have a 
dramatic impact in cancer cell biology. The early GalNAc O-glycosylation in the ER, may favor the 
action of the lectin domain of other GALNTs and stimulate clustered glycosylation, such as the 
putative clustered residues in MMP14. The mechanism of tumor progression dependent on increased 
expression and/or on relocation of GALNT1 may underlie the invasive phenotype associated to 
metastasis and poor outcome observed in liver cancer (Nguyen et al., 2017; Huang et al., 2015). Given 
the cell and tissue expression specificity of different GALNTs isoforms it would be of interest to know 
whether other GALNTs could influence similar mechanisms in different cancer models. Furthermore, 
the mechanisms leading to GALNTs relocation in tumor cells have generated much interest in the 
field (Herbomel et al., 2015) and future studies are warranted to fully clarify the molecular events 
triggering this pathway. 
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Noteably, the increased O-glycosylation initiation step through GALNTs may also lead to changes in 
the biosynthesis of several other cancer relevant glycan structures, such as sialyl-Tn and sialyl-T 
(Pinho and Reis, 2015). It is therefore expected that the GALA pathway, together with increased 
expression of other glycosyltransferases, frequently altered in cancers, may generate multiple glycan 
structures that could impact in the biology of the cancer cells and contribute to the increased 
aggressiveness of the tumors (Pinho and Reis, 2015).  
The study of Nguyen et al. addresses a still not fully clarified mechanism in cancer cells and goes 
beyond previous studies in unravelling its phenotypic consequences. This work adds new pieces to an 
intricate network that ultimately results in altered cancer cell glycosylation. The understanding of the 
regulatory mechanisms underlying these glycosylation modifications, particularly the factors 
controlling the glycosyltransferases location and activity, hold promise in unraveling novel targets 
for cancer clinical management. 
___________________________________________________________________________________ 
 
 
Figure 1. GALNTs subcellular localization affects protein O-glycosylation in cancer. Left: Classically, 
proteins synthesized in the endoplasmic reticulum (ER) undergo the initial step of protein GalNAc O-
glycosylation in the Golgi apparatus. This step is controlled by GALNTs that lead to GalNAcα1-O-
serine / threonine linked into O-glycoproteins. Several Golgi resident GALNTs catalyze this 
enzymatic step. The repertoire of GALNTs and other glycosyltransferases expressed define the final 
glycosylation features of the proteins produced by the cell. Right: Relocation of GALNT1 to the ER 
can lead to an augmented GalNAc O-glycosylation in several proteins expressed by the tumor cell, 
including the matrix metalloproteinase-14 (MMP14), enhancing its activity, potentiating extracellular 
matrix degradation and tumor progression. 
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